C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Google Disrupts Major Residential Proxy Network IPIDEA 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
The Maire - EuroChem Case: Three Lessons for Global Business 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
NEW YORK, May 19, 2017 -- Safirstein Metcalf LLP announces that a class action lawsuit has been filed against Neurotrope, Inc. (“Neurotrope” or the “Company”) (NASDAQ:NTRP) in the United States District Court for the Southern District of New York, and is filed on behalf of a class consisting of all persons or entities who acquired shares of Neurotrope between January 7, 2016, and April 28, 2017 (the "Class Period").
If you purchased Neurotrope securities during the Class Period, and would like more information about getting involved in the Neurotrope Shareholder Class Action, please call 1-800-221-0015, or email [email protected]. If you wish to serve as lead plaintiff, you must move the Court no later than July 17, 2017.
A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member
The complaint alleges that, throughout the class period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP Peter Safirstein, Esq. 1250 Broadway 27th Floor New York, NY 10001 1-800-221-0015
